Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer

12 Feb 2017

Abstract excerpt

Prostate cancer is driven by androgen stimulation of the androgen receptor (AR). The next-generation AR antagonist, enzalutamide, prolongs survival, but resistance and lethal disease eventually prevail. Emerging data suggest that the glucocorticoid receptor (GR) is upregulated in this context, stimulating expression of AR-target genes that permit continued growth despite AR blockade. However, countering this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hormonal and reproductive studies
Share to Prostate Cancer Treatment and Research
Share to Sexual Differentiation and Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28191869
DOI: 10.7554/elife.20183

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancerPMID 28191869Read ↗

A TBX2-driven signaling switch from androgen receptor to glucocorticoid receptor confers therapeutic resistance in prostate cancerSemantic proximity Read ↗

Glucocorticoid signaling delays castration-induced regression in murine models of prostate cancerSemantic proximity Read ↗

Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancerSemantic proximity Read ↗

Glucocorticoid receptor action in prostate cancer: the role of transcription factor crosstalkSemantic proximity Read ↗

Glucocorticoids and prostate cancer treatment: friend or foe?Semantic proximity Read ↗

<i>TMPRSS2-ERG</i> confers resistance to antiandrogens: mechanism and therapeutic implicationsSemantic proximity Read ↗

Glucocorticoid Receptor Regulates and Interacts with LEDGF/p75 to Promote Docetaxel Resistance in Prostate Cancer CellsSemantic proximity Read ↗

Androgen receptor-mediated assisted loading of the glucocorticoid receptor modulates transcriptional responses in prostate cancer cellsSemantic proximity Read ↗

Integrated metabolic and transcriptomic landscapes reveal an obligate reliance on exogenous steroid conversion for prostate cancer survivalSemantic proximity Read ↗

The Metabolism, Analysis, and Targeting of Steroid Hormones in Breast and Prostate Cancer.Semantic proximity Read ↗

SOX2 expression in prostate cancer drives resistance to nuclear hormone receptor signaling inhibition through the WEE1/CDK1 signaling axisSemantic proximity Read ↗

Loss of an Androgen-Inactivating and Isoform-Specific HSD17B4 Splice Form Enables Emergence of Castration-Resistant Prostate CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.